Innate Pharma SA (IPH)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

€1.562

Buy

€1.588

arrow-down€-0.042 (-2.61%)

Prices updated at 17 Dec 2025, 16:35 CET

Prices minimum 15 mins delay

Prices in EUR

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in developing immunotherapy drugs for cancer and inflammatory diseases.

FTSE EuroFirst 300

-0.03%

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Jonathan Elliott Dickinson, B.Sc. ,M.B.A.

CEO

Mr. Jonathan Elliott Dickinson, B.Sc. ,M.B.A.

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

174

Head office

117, Avenue de Luminy

Marseille

France

13009

+33 430303030

investors@innate-pharma.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Jonathan Elliott Dickinson, B.Sc. ,M.B.A. Chairman of the Executive Board and Chief Executive Officer	0.09m
Mr. Yannis Morel, PhD Member of the Executive Board, Executive Vice President and Chief Operating Officer	0.30m
Ms. Irina Staatz-Granzer, PhD Chairwoman of the Supervisory Board	0.04m
Professor Jean-Yves Blay, PhD Member of the Supervisory Board	-
Mr. Gilles Brisson Member of the Supervisory Board	0.03m
Dr. Veronique Chabernaud, M.D. Member of the Supervisory Board	0.06m
Ms. Odile Belzunce Vice President, Compliance, IT and Portfolio Management	-
Mr. Eric Vivier, D.V.M.,PhD Senior Vice President and Chief Scientific Officer	-
Ms. Odile Laurent, M.B.A.,PhD Vice President, Human Resources	-
Ms. Pascale Boissel Vice Chairwoman of the Supervisory Board	0.04m
Mr. Frederic Lombard, M.B.A. Chief Financial Officer	-
Ms. Sally Bennett Member of the Supervisory Board	-
Mr. Olivier Martinez Member of the Supervisory Board	-
Ms. Nicola Beltraminelli, PhD Vice President and Chief Development Officer	-
Mr. Henry Wheeler, M.Sc. Vice President, Investor Relations and Communications	-
Ms. Claire de Saint Blanquat Vice President, Legal and Corporate Affairs	-
Dr. Sonia Quaratino, M.D.,PhD Member of the Executive Board, Chief Medical Officer and Executive Vice President	0.35m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
CPR Asset Management	636,144
CPR Ambition France	636,144
La Française Asset Management	209,000
La Française Actions France PME	209,000
Saint Olive Gestion	170,000

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.